Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/27351
Title: | Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease. | Authors: | Parente P. ;Joshua A.M.;Pook D. ;Gibbs P.;Tran B.;Weickhardt A.;Schmidt A.;Anton A.;Shapiro J.;Wong S.;Azad A.;Kwan E. ;Spain L.;Muthusamy A.;Torres J.;Parnis F.;Goh J. | Institution: | (Schmidt, Muthusamy, Weickhardt) Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, Australia (Schmidt) Dana Farber Cancer Institute, Boston, MA, United States (Anton, Gibbs, Tran) Walter and Eliza Hall Institute, Melbourne, Australia (Anton, Spain, Parente) Eastern Health, Melbourne, Australia (Shapiro, Azad, Kwan, Spain, Parente, Pook) Monash University, Melbourne, Australia (Wong, Gibbs) Western Health, Melbourne, Australia (Azad, Tran) Peter MacCallum Cancer Centre, Australia (Kwan) Monash Health, Australia (Torres) Goulburn Valley Health, Shepparton, Australia (Parnis) Adelaide Cancer Centre, Adelaide, Australia (Parnis) University of Adelaide, Adelaide, Australia (Goh) Royal Brisbane and Women's Hospital, Brisbane, Australia (Joshua) St Vincent's Hospital, Sydney, Australia | Issue Date: | 11-Feb-2021 | Copyright year: | 2021 | Publisher: | Blackwell Publishing Ltd | Place of publication: | United Kingdom | Publication information: | Asia-Pacific Journal of Clinical Oncology. 17 (1) (pp 36-42), 2021. Date of Publication: February 2021. | Journal: | Asia-Pacific Journal of Clinical Oncology | Abstract: | Aim: Optimal treatment for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved, with many patients deriving benefit from the addition of docetaxel to androgen deprivation therapy (D-ADT). This study sought to define the therapy used and associated activity following D-ADT. Method(s): Retrospective analysis of patients with mHSPC treated with one or more cycles of D-ADT who were identified from a prospectively maintained multisite prostate cancer database of patients treated in a community or academic center setting in Australia. The primary endpoint of this study was first-line time to treatment failure (1L TTF) for subsequent treatment of metastatic Castrate Resistant Prostate Cancer (mCRPC), with secondary endpoints of prostate-specific antigen (PSA) reduction >50% and time from 1L to second-line (2L) treatment initiation. Result(s): A total of 93 patients received D-ADT for mHSPC, 85 (91%) had subsequent treatment for mCRPC. Median time to mCRPC (biochemical, clinical or radiographic) had been 14.8 months (95% confidence interval [CI], 11.9-16.5). 1L treatment was enzalutamide 47 patients (55%), abiraterone 23 (27%), cabazitaxel 7 (8%), docetaxel 4 (5%) and other therapies 4 (5%). Median 1L TTF was 6.3 months (95% CI, 4.9-7.6), PSA > 50% reduction was achieved in 32 of 89 patients (36%), median time from 1L to second-line treatment was 7.3 months (1.3-27.4), which did not differ significantly between treatment groups. Conclusion(s): Abiraterone, enzalutamide, cabazitaxel and docetaxel all demonstrate activity following progression on D-ADT. No difference in efficacy was detected between treatment options for mCRPC. Prospective trials investigating the optimal treatment sequence for prostate cancer following progression on D-ADT needed.Copyright © 2020 John Wiley & Sons Australia, Ltd | DOI: | http://monash.idm.oclc.org/login?url= http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/ajco.13447 |
PubMed URL: | 32970925 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32970925] | ISSN: | 1743-7555 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/27351 | Type: | Article | Subjects: | article Australia cancer patient cancer radiotherapy *castration resistant prostate cancer/di [Diagnosis] *castration resistant prostate cancer/dt [Drug Therapy] *castration resistant prostate cancer/rt [Radiotherapy] *castration resistant prostate cancer/th [Therapy] clinical effectiveness community hospital controlled study drug activity drug efficacy human major clinical study metastasis/dt [Drug Therapy] metastasis potential multiple cycle treatment priority journal prospective study retrospective study time to treatment treatment failure *treatment outcome treatment response time university hospital very elderly abiraterone/dt [Drug Therapy] abiraterone/pv [Special Situation for Pharmacovigilance] *androgen receptor antagonist/cm [Drug Comparison] *androgen receptor antagonist/dt [Drug Therapy] cabazitaxel/dt [Drug Therapy] cabazitaxel/pv [Special Situation for Pharmacovigilance] carboplatin/dt [Drug Therapy] carboplatin/pv [Special Situation for Pharmacovigilance] *docetaxel/cm [Drug Comparison] *docetaxel/dt [Drug Therapy] enzalutamide/dt [Drug Therapy] enzalutamide/pv [Special Situation for Pharmacovigilance] prostate specific antigen/ec [Endogenous Compound] metastatic hormone sensitive prostate cancer/dt [Drug Therapy] adult confidence interval androgen deprivation therapy aged drug efficacy human major clinical study metastasis / drug therapy metastasis potential multiple cycle treatment priority journal prospective study retrospective study time to treatment treatment failure *treatment outcome treatment response time university hospital very elderly controlled study confidence interval community hospital clinical effectiveness adult Australia Article androgen deprivation therapy aged drug activity *castration resistant prostate cancer / *diagnosis / *drug therapy / *radiotherapy / *therapy cancer radiotherapy cancer patient |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.